default author photo

Abdulazeez Salawu

University of Toronto - Princess Margaret Cancer Centre

SCHOLARLY PAPERS

1

DOWNLOADS

43

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer

Number of pages: 54 Posted: 14 Mar 2024
Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), Ontario Institute for Cancer Research, Ontario Institute for Cancer Research, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Tumor Immunotherapy Program, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre and University of Toronto - Princess Margaret Cancer Centre
Downloads 43 (1,157,785)

Abstract:

Loading...

Immunotherapy, biomarkers, colorectal, pancreatic, cancer, cold tumors